一、监事会会议召开情况 证券代码：688136 证券简称：科兴制药 公告编号：2025-038 科兴生物制药股份有限公司 第二届监事会第二十二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 科兴生物制药股份有限公司（以下简称"公司"）第二届监事会第二十二次 会议于 2025 年 6 月 23 日以现场表决的方式召开。会议通知已于 2025 年 6 月 20 日发出。本次会议应出席监事 3 人，实际出席监事 3 人。 会议由监事会主席江海燕主持。会议召开符合有关法律、法规、规章和《公 司章程》的规定。 二、监事会会议审议情况 （一）审议通过《关于调整 2024 年限制性股票激励计划授予价格的议案》 公司监事会认为：公司 2024 年年度权益分派已实施完毕，根据《上市公司 股权激励管理办法》（以下简称"《管理办法》"）和公司《2024 年限制性股票激 励计划（草案）》（以下简称"《激励计划》"）的相关规定，监事会经过认真核查， 同意对本次激励计划的授予价格进行相应调整，由 12.00 元/股调整为 11.92 ...

综上，监事会同意公司为本次符合归属条件的激励对象办理限制性股票的 归属，上述事项符合相关法律、法规及规范性文件所规定的条件，不存在损害 公司及股东利益的情形。 科兴生物制药股份有限公司 监事会 2025 年 6 月 23 日 监事会关于 2024 年限制性股票激励计划第一个归属期归属 名单的核查意见 科兴生物制药股份有限公司（以下简称"公司"）监事会依据《中华人民 共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称 "《管理办法》"）、《上海证券交易所科创板股票上市规则》（以下简称 "《上市规则》"）和《科兴生物制药股份有限公司章程》（以下简称"《公 司章程》"）等有关规定，对本次限制性股票激励计划归属的激励对象名单进 行审核，发表核查意见如下： 本次拟归属的激励对象符合《公司法》《证券法》等法律、法规和规范性 文件以及《公司章程》规定的任职资格，符合《管理办法》《上市规则》等法 律、法规和规范性文件规定的激励对象条件，符合本激励计划规定的激励对象 范围，其作为公司本激励计划激励对象的主体资格合法、有效，激励对象获授 限制性股 ...

证券代码：688136 证券简称：科兴制药 公告编号：2025-037 科兴生物制药股份有限公司 第二届董事会第二十六次会议决议公告 会议由董事长邓学勤主持，公司监事，部分高管列席会议。会议召开符合有 关法律、法规、规章和《公司章程》的规定，会议决议合法、有效。 二、董事会会议审议情况 经各位董事认真审议，会议形成了如下决议： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 科兴生物制药股份有限公司（以下简称"公司"）第二届董事会第二十六次 会议于 2025 年 6 月 23 日在深圳市南山区创益科技大厦 B 栋 19 楼会议室以现场 结合通讯的方式召开。本次会议通知于 2025 年 6 月 20 日通过邮件的方式送达各 位董事。本次会议应出席董事 7 人，实际出席董事 7 人。 （一）审议通过《关于调整 2024 年限制性股票激励计划授予价格的议案》 公司 2024 年年度权益分派已实施完毕，根据《上市公司股权激励管理办法》 （以下简称"《管理办法》"）、《2024 年限制性股票激励计划（草案）》 ...

董事会薪酬与考核委员会 关于 2024 年限制性股票激励计划第一个归属期归属名单的 核查意见 科兴生物制药股份有限公司（以下简称"公司"）董事会薪酬与考核委员 会依据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、《上市公司股权激励管理办 法》（以下简称"《管理办法》"）、《上海证券交易所科创板股票上市规 则》（以下简称"《上市规则》"）和《科兴生物制药股份有限公司章程》 （以下简称"《公司章程》"）等有关规定，对本次限制性股票激励计划归属 的激励对象名单进行审核，发表核查意见如下： 本次拟归属的激励对象符合《公司法》《证券法》等法律、法规和规范性 文件以及《公司章程》规定的任职资格，符合《管理办法》《上市规则》等法 律、法规和规范性文件规定的激励对象条件，符合本激励计划规定的激励对象 范围，其作为公司本激励计划激励对象的主体资格合法、有效，激励对象获授 限制性股票的归属条件已经成就。 综上，董事会薪酬与考核委员会同意公司为本次符合归属条件的激励对象 办理限制性股票的归属，上述事项符合相关法律、法规及规范性文件所规定的 条件，不存在损害公司及股东利益的 ...

Core Viewpoint - The company has adjusted the maximum repurchase price of its shares from RMB 46.83 per share to RMB 46.75 per share following the implementation of the 2024 annual equity distribution [1][3]. Summary by Sections Share Repurchase Basic Information - The company approved a share repurchase plan on March 17, 2025, allowing for a minimum repurchase amount of RMB 30 million and a maximum of RMB 60 million through the Shanghai Stock Exchange [1][4]. - The repurchased shares will be used for employee stock ownership plans or equity incentives and must be transferred within three years after the announcement of the repurchase results [1][4]. Reason for Adjusting the Maximum Repurchase Price - The adjustment in the repurchase price is based on the company's 2024 annual profit distribution plan, which includes a cash dividend of RMB 0.80 per 10 shares [2][3]. - The record date for the equity distribution is June 11, 2025, and the ex-dividend date is June 12, 2025 [2][3]. Details of the Price Adjustment - The new maximum repurchase price is calculated as follows: (previous maximum price - cash dividend) / (1 + change in circulating shares ratio) [3]. - Since the company is only distributing cash dividends and not changing the capital structure, the circulating shares ratio remains 0, leading to an adjusted maximum repurchase price of approximately RMB 46.75 per share [3][4]. Other Matters - Aside from the price adjustment, all other aspects of the share repurchase plan remain unchanged, and the company will comply with relevant regulations during the repurchase period [4].

证券代码：688136 证券简称：科兴制药 公告编号：2025-036 科兴生物制药股份有限公司 关于 2024 年年度权益分派实施后调整回购价格上限的公告 本公司董事会、全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 科兴生物制药股份有限公司（以下简称"公司"）2024 年年度权益分派 已实施完毕，公司以集中竞价交易方式回购股份价格上限由不超过人民币 46.83 元/股（含）调整为不超过人民币 46.75 元/股（含），回购价格上限调整起始日 为 2025 年 6 月 12 日（2024 年年度权益分派除权除息日）。 一、回购股份的基本情况 公司于 2025 年 3 月 17 日召开第二届董事会第二十一次会议，审议通过了《关 于以集中竞价交易方式回购公司股份方案的议案》，同意公司使用不低于人民币 3,000 万元（含），不超过人民币 6,000 万元（含）的自有资金和回购专项贷款 通过上海证券交易所交易系统以集中竞价交易方式回购公司股份，本次回购股份 在未来适宜时机用于股权激励或员工持股计划，并在公司披露股份回购实施结 ...

Group 1 - The first "doubling fund" in the public fund market for 2025 is the Huatai-PineBridge Hong Kong Advantage Selection A, which has achieved a 99.5% year-to-date return as of June 13, 2025, leading the entire market [1][2] - Among the top 10 funds for year-to-date returns in 2025, 8 are heavily invested in pharmaceutical companies, particularly in the innovative drug sector [1][2] - The innovative drug sector has seen significant growth, with the Wind Innovative Drug Concept Index rising over 25% and the Hang Seng Innovative Drug Index increasing over 53% since April 9, 2025 [2][3] Group 2 - Notable stocks in the innovative drug sector have experienced substantial price increases, with Shuyou Pharmaceutical leading at a 478.84% increase, followed by Sanofi Health at 129.81% [3][4] - The top-performing funds have a high concentration of investments in innovative drug companies, with the most frequently held stock being Kelong Biotechnology-B, which has also doubled in price [4][5] - Fund managers of the top-performing funds are predominantly new faces, with half of them having less than two years of investment experience [5][6] Group 3 - Zhang Wei, the manager of Huatai-PineBridge Hong Kong Advantage Selection A, has maintained a strong focus on the pharmaceutical sector, with the fund's top holdings consistently being in the biopharmaceutical industry [7][8] - The fund has shown resilience despite previous years of losses, with a significant recovery in 2025 attributed to the performance of its long-held innovative drug stocks [9][10] - Zhang Wei's investment strategy emphasizes long-term perspectives and stability in holdings, focusing on companies with global competitiveness and growth potential in the pharmaceutical and biotech sectors [10][11] Group 4 - The performance disparity among active equity funds in 2025 is notable, with 12 funds experiencing declines of over 20%, including several managed by Jin Zicai [13][14] - Jin Zicai's aggressive investment style has led to high turnover rates and concentrated positions, which can result in significant volatility [15][16] - The overall market sentiment towards innovative drugs remains positive, with expectations for continued growth driven by domestic medical demand recovery and supportive policies [10][11]

华福证券认为，港股创新药（含Pharma）为医药板块中最强势的板块，其次为创新药产业链CRO板 块，创新药已成为市场认可的主线之一，个股方面从主流一二线标的，行情亦在向有创新药布局或BD 预期的中药或仿制药标的扩展。短期创新药建议积极拥抱龙头和一线标的。 （本文机构观点来自持牌证券机构，不构成任何投资建议，亦不代表平台观点，请投资人独立判断和决 策。） 消息面上，据央视新闻，6月13日国务院常务会议召开研究优化药品和耗材集采有关举措。会议指出， 要加强药品和耗材集采政策评估，总结经验、补齐短板，推动集采工作规范化制度化常态化开展。要更 好促进"三医"协同发展和治理，完善公立医院补偿机制，支持医药企业提高创新能力，更好满足群众多 元化就医用药需求。要加强对药品和耗材生产、流通、使用全链条质量监管，扎实推进仿制药质量和疗 效一致性评价，让人民群众用药放心安心。 东吴证券指出，创新药BD推动及优秀临床数据下，看好的医药子行业排序分别为：创新药>CXO>中药 >医疗器械>药店>医药商业等。具体标的选择思路：从成长性角度选股，主要集中创新药领域；从左侧 角度选股，主要集中在CXO、医疗器械。 6月16日，创新药概念小幅 ...

Core Viewpoint - Kexing Pharmaceutical (688136.SH) plans to sell its wholly-owned subsidiary, Shenzhen Tong'an Pharmaceutical Co., Ltd., for 15 million yuan to reduce management costs and improve asset operation efficiency [1][13]. Group 1: Company Performance - Kexing Pharmaceutical's stock price has doubled since the beginning of the year, with a significant increase of 156.50% from 21.86 yuan per share at the end of 2024 to 56.07 yuan on June 4 [6][10]. - The company reported a revenue of 14.07 billion yuan in 2024, an increase of 11.75% year-on-year, and achieved a net profit of 31 million yuan, marking a turnaround from previous losses [10][11]. - Despite the revenue growth, the company's R&D expenses significantly decreased to 168 million yuan in 2024, down 51.30% from the previous year [11][13]. Group 2: Shareholder Actions - The controlling shareholder, Shenzhen Keyi Pharmaceutical Holdings Co., Ltd., plans to reduce its stake by up to 3%, potentially cashing out over 336 million yuan based on the stock price at the time of the announcement [4][5]. - This is the first time since Kexing Pharmaceutical's IPO that the major shareholder has announced a reduction in holdings, raising market concerns about the intention behind the move [3][5]. Group 3: Market Reactions - Following the announcement of the major shareholder's reduction plan, Kexing Pharmaceutical's stock price fell to 50.95 yuan per share by June 12 [8]. - Market skepticism arose due to the significant stock price increase prior to the reduction announcement, with some investors questioning the motives behind the shareholder's decision [5][6].

Group 1 - The recombinant protein concept sector declined by 0.82%, ranking among the top declines in concept sectors, with notable declines in companies such as Kexing Pharmaceutical, Jieya Co., and Yipinhong [1] - Among the 14 stocks that rose, Furuida, Borui Pharmaceutical, and Saiseng Pharmaceutical had the highest increases of 10.06%, 3.54%, and 2.90% respectively [1] - The sector experienced a net outflow of 232 million yuan from main funds, with 35 stocks seeing net outflows, and five stocks experiencing outflows exceeding 30 million yuan [2] Group 2 - The top net outflow stock was Saiseng Pharmaceutical, with a net outflow of 65.48 million yuan, followed by Xilong Science, Zhongyuan Qihe, and Borui Pharmaceutical with net outflows of 61.32 million yuan, 53.12 million yuan, and 51.87 million yuan respectively [2][3] - The stocks with the highest net inflows included Furuida, Maiwei Bio, and Ruizhi Pharmaceutical, with net inflows of 189 million yuan, 39.29 million yuan, and 18.25 million yuan respectively [2] - The trading volume and price changes of various stocks in the recombinant protein sector indicate significant market activity, with Saiseng Pharmaceutical showing a trading rate of 35.58% despite the outflow [3]